Posts Tagged ‘Covid trial’
Nasodine COVID-19 Trial Achieves Primary Endpoint
07 Aug 2023
Highlights Firebrick Pharma Limited is pleased to announce that its Phase 2 trial of Nasodine® Nasal Spray in COVID-19 achieved its primary endpoint. The primary endpoint was the reduction in viral load of SARS-CoV-2 over 4 days, based on culturable virus from throat and nasal swabs. Nasodine treatment resulted in 100% reduction by day 4,…
Nasodine COVID-19 Trial Concludes Recruitment – Results in June 2023
03 Apr 2023
Firebrick Pharma is pleased to announce that its Phase 2 COVID-19 trial of Nasodine® Nasal Spray has closed for recruitment.
Nasodine trial in COVID-19 started
26 Apr 2022
Firebrick Pharma is pleased to announce that the Phase 2 COVID-19 clinical trial for Nasodine® Nasal Spray (“Nasodine”) in South Africa has commenced, with the first patient now recruited.